Details of the Drug

General Information of Drug (ID: DMNZWL7)

Drug Name

Moclobemide

Synonyms

Arima; Aurorex; Aurorix; Deprenorm; Feraken; Manerix; Moclaime; Moclamide; Moclamine; Moclix; Moclobamide; Moclobemid; Moclobemida; Moclobemidum; Moclobeta; Moclodura; Moclonorm; NovoMoclobemide; NuMoclobemide; Rimoc; Alphapharm Brand of Moclobemide; Alpharma Brand of Moclobemide; Apo Moclobemide; Apotex Brand of Moclobemide; Azupharma Brand of Moclobemide; BC Brand of Moclobemide; Betapharm Brand of Moclobemide; Bull Brand of Moclobemide; Chem mart Brand of Moclobemide; Chem mart Moclobemide; Ct Arzneimittel Brand of Moclobemide; DBL Moclobemide; Esparma Brand of Moclobemide; Faulding Brand of Moclobemide; GenRX Moclobemide; Healthsense Brand of Moclobemide; Healthsense Moclobemide; Hexal Brand of Moclobemide; Hoffmann La Roche Brand of Moclobemide; Kendrick Brand of Moclobemide; Merck dura Brand of Moclobemide; Moclobemid AZU; Moclobemid Puren; Moclobemid Stada; Moclobemid ratiopharm; Moclobemid von ct; Moclobemide Alphapharm Brand; Moclobemide Alpharma Brand; Moclobemide Apotex Brand; Moclobemide Azupharma Brand; Moclobemide BC Brand; Moclobemide Bull Brand; Moclobemide Faulding Brand; Moclobemide Healthsense Brand; Moclobemide Hexal Brand; Moclobemide Kendrick Brand; Moclobemide Novopharm Brand; Moclobemide Pharmascience Brand; Moclobemide Roche Brand; Moclobemide Stadapharm Brand; Moclobemide Temmler Brand; Moclobemide betapharm Brand; Moclobemide esparma Brand; Moclobemide ratiopharm Brand; Novo Moclobemide; Novopharm Brand of Moclobemide; Nu Moclobemide; Nu Pharm Brand of Moclobemide; PMS Moclobemide; Pharmascience Brand of Moclobemide; Ratiopharm Brand of Moclobemide; Roche Brand of Moclobemide; Stadapharm Brand of Moclobemide; Temmler Brand of Moclobemide; Terry White Chemists Brand of Moclobemide; Terry White Chemists Moclobemide; CBMicro_048319; Moclobemid 1A Pharma; Moclobemid1A Pharma; Moclobemide 1A Brand; Ro 11 1163; AZU, Moclobemid; Apo-Moclobemide; Aurorix (TN); Ct-Arzneimittel Brand of Moclobemide; Hoffmann-La Roche Brand of Moclobemide; Manerix (TN); Moclobemid-1A Pharma; Moclobemid-Puren; Moclobemid-ratiopharm; Moclobemida [INN-Spanish]; Moclobemide Nu-Pharm Brand; Moclobemide ct-Arzneimittel Brand; Moclobemide, Chem mart; Moclobemide, DBL; Moclobemide, GenRX; Moclobemide, Healthsense; Moclobemidum [INN-Latin]; Novo-Moclobemide; Nu-Moclobemide; Nu-Pharm Brand of Moclobemide; PMS-Moclobemide; Ro 11-1163; Stada, Moclobemid; Von ct, Moclobemid; GNF-PF-695; Moclobemide (USAN/INN); Moclobemide [USAN:BAN:INN]; Moclobemide [USAN:INN:BAN]; Ro 11-1163/000; Ro-11-1163; P-Chloro-N-(2-morpholinoethyl)benzamide; 1A Brand of Moclobemide; 4-Chlor-N-(2-morpholinoethyl)benzamid; 4-Chloro-N-(2-(4-morpholinyl)ethyl)benzamide; 4-Chloro-N-(2-morpholin-4-yl-ethyl)-benzamide; 4-chloro-N-(2-morpholin-4-ylethyl)benzamide; 4-chloro-N-[2-(morpholin-4-yl)ethyl]benzamide

Indication

Disease Entry	ICD 11	Status	REF
Depression	6A70-6A7Z	Approved	[1]
Skin imperfections	EK71	Patented	[2]
------------------------------------------------------------------------------------

Therapeutic Class

Antidepressants

Affected Organisms

Humans and other mammals

ATC Code

N06AG02: Moclobemide

N06AG: Monoamine oxidase A inhibitors

N06A: ANTIDEPRESSANTS

N06: PSYCHOANALEPTICS

N: NERVOUS SYSTEM

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

268.74

Logarithm of the Partition Coefficient (xlogp)

1.5

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 2-6 h [3]
Bioavailability: The bioavailability of drug is 70% [3]
Clearance: The clearance of drug is 30-78 L/h [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 1 - 2 hours [5]
Metabolism: The drug is metabolized via the liver [6]
Unbound Fraction: The unbound fraction of drug in plasma is 0.77% [5]
Vd: The volume of distribution (Vd) of drug is 1-1.5 L/kg [4]

Chemical Identifiers

Formula: C13H17ClN2O2
IUPAC Name: 4-chloro-N-(2-morpholin-4-ylethyl)benzamide
Canonical SMILES: C1COCCN1CCNC(=O)C2=CC=C(C=C2)Cl
InChI: InChI=1S/C13H17ClN2O2/c14-12-3-1-11(2-4-12)13(17)15-5-6-16-7-9-18-10-8-16/h1-4H,5-10H2,(H,15,17)
InChIKey: YHXISWVBGDMDLQ-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 4235
ChEBI ID: CHEBI:83531
CAS Number: 71320-77-9
UNII: PJ0Y7AZB63
DrugBank ID: DB01171
TTD ID: D01ZSO
VARIDT ID: DR00838
INTEDE ID: DR1103

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Monoamine oxidase (MAO)	TT32XQJ	NOUNIPROTAC	Inhibitor	[2]
Monoamine oxidase type A (MAO-A)	TT3WG5C	AOFA_HUMAN	Inhibitor	[7]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[8]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[9]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[10]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Amine oxidase A (MAOA)	OT8NIWMQ	AOFA_HUMAN	Gene/Protein Processing	[11]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Depression

ICD Disease Classification

6A70-6A7Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Monoamine oxidase type A (MAO-A)	DTT	MAOA	8.14E-01	0.05	0.1
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	2.40E-01	-3.31E-02	-1.97E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	7.30E-01	-1.91E-02	-1.41E-01
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	1.90E-01	-9.81E-03	-5.96E-02

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7428).
2	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
3	Odanacatib, a selective cathepsin K inhibitor, demonstrates comparable pharmacodynamics and pharmacokinetics in older men and postmenopausal women. J Clin Endocrinol Metab. 2014 Feb;99(2):552-60. doi: 10.1210/jc.2013-1688. Epub 2013 Nov 25.
4	Monamine Oxidase Inhibitors
5	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6	Zagelbaum NK, Yandrapalli S, Nabors C, Frishman WH: Bempedoic Acid (ETC-1002): ATP Citrate Lyase Inhibitor: Review of a First-in-Class Medication with Potential Benefit in Statin-Refractory Cases. Cardiol Rev. 2019 Jan/Feb;27(1):49-56. doi: 10.1097/CRD.0000000000000218.
7	Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings. Hum Psychopharmacol. 2002 Dec;17(8):401-5.
8	Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clin Pharmacol Ther. 1995 Jun;57(6):670-7.
9	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
10	Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19. Clin Pharmacol Ther. 2001 Apr;69(4):266-73.
11	Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors. J Med Chem. 2011 Oct 27;54(20):7127-37.